1-3 of 3
Xuechan Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Free
Raajit Rampal, John Mascarenhas, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron Gerds, Francesca Palandri, Vikas Gupta, Sung-Eun Lee, Alessandro Lucchesi, Andrew Kuykendall, Stephen Oh, Andrea Patriarca, alberto Alvarez-Larran, David Lavie, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Monika Wroclawska, Xuechan Li, Thomas Lehmann, Harald Maier, Claire Harrison, Alessandro Vannucchi
Journal: Blood
Blood (2025) 146 (Supplement 1): 910.
https://doi.org/10.1182/blood-2025-910
Published: 2025
Journal Articles

Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease: the REACH4 study

Free
Clinical Trials & Observations
Franco Locatelli, Hyoung Jin Kang, Bénédicte Bruno, Virginie Gandemer, Fanny Rialland, Maura Faraci, Yoshiyuki Takahashi, Katsuyoshi Koh, Henrique Bittencourt, Grace Cleary, Christine Rosko, Xuechan Li, Annie St Pierre, Anirudh Prahallad, Cristina Diaz-de-Heredia
Journal: Blood
Blood (2024) 144 (20): 2095–2106.
https://doi.org/10.1182/blood.2023022565
Published: 2024
Includes: Supplemental data
Journal Articles

Ruxolitinib in Patients With Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of Efficacy and Safety From the Phase III REACH3 Study

Free
Robert Zeiser, Domenico Russo, Ron Ram, Shahrukh K Hashmi, Ronjon Chakraverty, Jan Moritz Middeke, Maurizio Musso, Sebastian Giebel, Ant Uzay, Peter Langmuir, Nada Hamad, Xuechan Li, Maanasa Gowda, Tommaso Stefanelli, Stephanie J. Lee, Takanori Teshima, Franco Locatelli
Journal: Blood
Blood (2023) 142 (Supplement 1): 654.
https://doi.org/10.1182/blood-2023-172590
Published: 2023